BIAF vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BIAF vs LLY: Head-to-Head Comparison
This page compares bioAffinity Technologies, Inc. (BIAF) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.